 Michael Wilson
Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pathology | 7 | 2018 | 22 | 3.430 |
Why?
| | Clinical Laboratory Techniques | 9 | 2019 | 94 | 3.090 |
Why?
| | Global Health | 8 | 2024 | 329 | 2.650 |
Why?
| | Pathology, Clinical | 5 | 2018 | 36 | 1.760 |
Why?
| | Diagnostic Techniques and Procedures | 3 | 2023 | 20 | 1.650 |
Why?
| | Clinical Laboratory Services | 3 | 2018 | 8 | 1.210 |
Why?
| | Laboratories | 6 | 2022 | 109 | 1.060 |
Why?
| | Pathologists | 2 | 2024 | 17 | 1.020 |
Why?
| | Autopsy | 3 | 2014 | 92 | 0.920 |
Why?
| | Health Services Accessibility | 3 | 2023 | 903 | 0.840 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2015 | 98 | 0.830 |
Why?
| | Education, Medical | 4 | 2015 | 254 | 0.800 |
Why?
| | Malaria | 2 | 2013 | 59 | 0.770 |
Why?
| | Quality of Health Care | 3 | 2018 | 610 | 0.730 |
Why?
| | Internship and Residency | 3 | 2015 | 1058 | 0.690 |
Why?
| | Antitubercular Agents | 2 | 2013 | 200 | 0.680 |
Why?
| | Communicable Diseases | 3 | 2008 | 152 | 0.640 |
Why?
| | Health Services Needs and Demand | 2 | 2018 | 263 | 0.630 |
Why?
| | Tuberculosis | 2 | 2013 | 273 | 0.620 |
Why?
| | Mycobacterium tuberculosis | 2 | 2013 | 309 | 0.610 |
Why?
| | Early Diagnosis | 1 | 2019 | 233 | 0.580 |
Why?
| | Education, Medical, Continuing | 2 | 2018 | 123 | 0.560 |
Why?
| | Health Equity | 1 | 2019 | 87 | 0.550 |
Why?
| | Reimbursement Mechanisms | 2 | 2015 | 84 | 0.550 |
Why?
| | Humans | 58 | 2024 | 129847 | 0.540 |
Why?
| | Pathology, Surgical | 1 | 2017 | 9 | 0.540 |
Why?
| | Developing Countries | 5 | 2021 | 284 | 0.530 |
Why?
| | Parasitemia | 2 | 2013 | 11 | 0.520 |
Why?
| | Calciphylaxis | 1 | 2015 | 2 | 0.490 |
Why?
| | Search Engine | 1 | 2015 | 9 | 0.490 |
Why?
| | Artificial Intelligence | 1 | 2018 | 245 | 0.490 |
Why?
| | Microbiology | 1 | 2015 | 24 | 0.480 |
Why?
| | Diagnostic Tests, Routine | 2 | 2017 | 104 | 0.480 |
Why?
| | Health Services Misuse | 1 | 2015 | 35 | 0.470 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 716 | 0.470 |
Why?
| | Malaria, Vivax | 1 | 2014 | 4 | 0.460 |
Why?
| | Antimalarials | 1 | 2014 | 30 | 0.450 |
Why?
| | Malaria, Falciparum | 1 | 2014 | 27 | 0.450 |
Why?
| | Pathology, Molecular | 1 | 2014 | 25 | 0.450 |
Why?
| | Efficiency | 1 | 2015 | 92 | 0.440 |
Why?
| | Drug Resistance, Bacterial | 3 | 2013 | 175 | 0.440 |
Why?
| | Medical Laboratory Personnel | 1 | 2014 | 7 | 0.440 |
Why?
| | Neoplasms | 3 | 2018 | 2454 | 0.420 |
Why?
| | Plasmodium | 1 | 2013 | 13 | 0.420 |
Why?
| | Leiomyoma | 1 | 2014 | 73 | 0.410 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2013 | 43 | 0.410 |
Why?
| | Uterine Neoplasms | 1 | 2014 | 100 | 0.400 |
Why?
| | Students, Medical | 2 | 2014 | 323 | 0.390 |
Why?
| | Population Surveillance | 2 | 2018 | 439 | 0.380 |
Why?
| | Cooperative Behavior | 1 | 2014 | 433 | 0.360 |
Why?
| | Otitis Media | 2 | 2024 | 160 | 0.360 |
Why?
| | Bacteriological Techniques | 1 | 2011 | 70 | 0.350 |
Why?
| | United States Public Health Service | 1 | 2010 | 9 | 0.340 |
Why?
| | Immunoassay | 2 | 2011 | 108 | 0.330 |
Why?
| | Genomics | 1 | 2014 | 716 | 0.320 |
Why?
| | Communication | 1 | 2015 | 847 | 0.320 |
Why?
| | Physicians | 2 | 2015 | 875 | 0.320 |
Why?
| | Referral and Consultation | 1 | 2014 | 735 | 0.310 |
Why?
| | Community Health Services | 1 | 2010 | 229 | 0.290 |
Why?
| | Health Personnel | 1 | 2014 | 658 | 0.290 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2009 | 146 | 0.290 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 36 | 0.280 |
Why?
| | Bone Diseases | 1 | 2008 | 57 | 0.280 |
Why?
| | Joint Diseases | 1 | 2008 | 57 | 0.270 |
Why?
| | Haemophilus influenzae | 2 | 2024 | 64 | 0.270 |
Why?
| | Microbiological Techniques | 2 | 2008 | 30 | 0.270 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1033 | 0.260 |
Why?
| | Latent Tuberculosis | 2 | 2018 | 67 | 0.260 |
Why?
| | Skin Diseases | 1 | 2008 | 143 | 0.250 |
Why?
| | Forensic Pathology | 1 | 2005 | 7 | 0.250 |
Why?
| | Government Agencies | 1 | 2005 | 15 | 0.250 |
Why?
| | Health Facility Closure | 1 | 2005 | 8 | 0.240 |
Why?
| | Urinary Tract Infections | 2 | 2004 | 151 | 0.240 |
Why?
| | Academies and Institutes | 1 | 2005 | 50 | 0.240 |
Why?
| | Military Medicine | 1 | 2005 | 63 | 0.230 |
Why?
| | Conjunctivitis, Bacterial | 1 | 2024 | 11 | 0.230 |
Why?
| | Urine | 1 | 2004 | 60 | 0.220 |
Why?
| | Amoxicillin | 1 | 2024 | 30 | 0.220 |
Why?
| | Influenza, Human | 1 | 2009 | 602 | 0.210 |
Why?
| | Armed Conflicts | 1 | 2023 | 10 | 0.210 |
Why?
| | Sensitivity and Specificity | 3 | 2013 | 1847 | 0.200 |
Why?
| | Meta-Analysis as Topic | 2 | 2013 | 170 | 0.200 |
Why?
| | Isoniazid | 2 | 2013 | 63 | 0.190 |
Why?
| | Rifampin | 2 | 2013 | 83 | 0.190 |
Why?
| | Microbial Sensitivity Tests | 3 | 2013 | 349 | 0.190 |
Why?
| | World Health Organization | 3 | 2020 | 110 | 0.180 |
Why?
| | Urban Population | 3 | 2018 | 443 | 0.180 |
Why?
| | Interferon-gamma Release Tests | 2 | 2018 | 32 | 0.180 |
Why?
| | Logical Observation Identifiers Names and Codes | 1 | 2020 | 1 | 0.180 |
Why?
| | Clinical Laboratory Information Systems | 1 | 2020 | 6 | 0.180 |
Why?
| | Levamisole | 2 | 2011 | 19 | 0.170 |
Why?
| | Point-of-Care Systems | 2 | 2019 | 149 | 0.170 |
Why?
| | Cost of Illness | 1 | 2022 | 277 | 0.170 |
Why?
| | Women's Health | 2 | 2013 | 364 | 0.170 |
Why?
| | Gonorrhea | 1 | 2021 | 57 | 0.170 |
Why?
| | Chlamydia Infections | 1 | 2021 | 72 | 0.170 |
Why?
| | Anti-Bacterial Agents | 3 | 2024 | 1708 | 0.170 |
Why?
| | Diagnosis | 1 | 2019 | 12 | 0.170 |
Why?
| | Clinical Coding | 1 | 2019 | 20 | 0.160 |
Why?
| | Diagnostic Imaging | 1 | 2021 | 326 | 0.150 |
Why?
| | Cocaine | 2 | 2011 | 150 | 0.150 |
Why?
| | Socioeconomic Factors | 2 | 2021 | 1214 | 0.150 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2019 | 95 | 0.150 |
Why?
| | Africa South of the Sahara | 1 | 2018 | 42 | 0.150 |
Why?
| | Urban Health Services | 1 | 2018 | 61 | 0.140 |
Why?
| | Health Education | 2 | 2018 | 335 | 0.140 |
Why?
| | Infant | 5 | 2024 | 9018 | 0.140 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 196 | 0.140 |
Why?
| | Leukemoid Reaction | 1 | 2016 | 3 | 0.140 |
Why?
| | GATA1 Transcription Factor | 1 | 2016 | 18 | 0.130 |
Why?
| | Acute Disease | 3 | 2024 | 980 | 0.130 |
Why?
| | Mass Screening | 2 | 2018 | 1192 | 0.130 |
Why?
| | Public Health | 2 | 2018 | 487 | 0.130 |
Why?
| | Point Mutation | 1 | 2016 | 224 | 0.120 |
Why?
| | Africa | 2 | 2015 | 99 | 0.120 |
Why?
| | Diseases in Twins | 1 | 2016 | 175 | 0.120 |
Why?
| | Clinical Audit | 1 | 2015 | 11 | 0.120 |
Why?
| | Cost Control | 1 | 2015 | 39 | 0.120 |
Why?
| | Utilization Review | 1 | 2015 | 36 | 0.120 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 27 | 0.120 |
Why?
| | Benchmarking | 1 | 2016 | 176 | 0.120 |
Why?
| | Child, Preschool | 5 | 2024 | 10522 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2016 | 229 | 0.110 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1282 | 0.110 |
Why?
| | Hospitals | 1 | 2019 | 649 | 0.110 |
Why?
| | Drug Contamination | 2 | 2011 | 51 | 0.110 |
Why?
| | Medication Therapy Management | 1 | 2015 | 72 | 0.110 |
Why?
| | Agranulocytosis | 2 | 2011 | 30 | 0.110 |
Why?
| | Female | 12 | 2024 | 68829 | 0.110 |
Why?
| | Infection Control | 1 | 2015 | 143 | 0.110 |
Why?
| | Parasite Load | 1 | 2013 | 8 | 0.110 |
Why?
| | Antigens, Protozoan | 1 | 2013 | 22 | 0.100 |
Why?
| | Adult | 10 | 2021 | 35634 | 0.100 |
Why?
| | Cross Infection | 1 | 2015 | 219 | 0.100 |
Why?
| | Time Factors | 2 | 2013 | 6550 | 0.100 |
Why?
| | Parasitology | 1 | 2012 | 8 | 0.100 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2013 | 123 | 0.100 |
Why?
| | Proteome | 1 | 2016 | 440 | 0.100 |
Why?
| | Anti-Infective Agents | 1 | 2015 | 249 | 0.100 |
Why?
| | HIV | 1 | 2013 | 227 | 0.090 |
Why?
| | Coinfection | 1 | 2013 | 131 | 0.090 |
Why?
| | DNA, Bacterial | 1 | 2013 | 323 | 0.090 |
Why?
| | Child | 7 | 2024 | 20962 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3089 | 0.090 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2011 | 55 | 0.090 |
Why?
| | Clinical Competence | 1 | 2018 | 1020 | 0.090 |
Why?
| | Infant, Newborn | 3 | 2016 | 5772 | 0.090 |
Why?
| | Down Syndrome | 1 | 2016 | 478 | 0.080 |
Why?
| | Proteomics | 1 | 2016 | 1058 | 0.080 |
Why?
| | Cocaine-Related Disorders | 1 | 2011 | 108 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 222 | 0.080 |
Why?
| | Escherichia coli | 2 | 2004 | 766 | 0.080 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 443 | 0.080 |
Why?
| | United States | 4 | 2016 | 13913 | 0.080 |
Why?
| | Pregnancy | 3 | 2016 | 6423 | 0.080 |
Why?
| | Comorbidity | 1 | 2013 | 1551 | 0.070 |
Why?
| | Quality Control | 1 | 2008 | 162 | 0.070 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2008 | 32 | 0.070 |
Why?
| | Histocytochemistry | 1 | 2008 | 80 | 0.070 |
Why?
| | Adolescent | 5 | 2021 | 20451 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1951 | 0.070 |
Why?
| | Young Adult | 3 | 2021 | 12467 | 0.070 |
Why?
| | Primary Health Care | 1 | 2018 | 1687 | 0.070 |
Why?
| | Tuberculin Test | 2 | 2018 | 36 | 0.070 |
Why?
| | Peripheral Vascular Diseases | 1 | 2008 | 102 | 0.070 |
Why?
| | Quality Improvement | 1 | 2015 | 1112 | 0.070 |
Why?
| | Protective Clothing | 1 | 2006 | 14 | 0.060 |
Why?
| | Museums | 1 | 2005 | 11 | 0.060 |
Why?
| | Male | 10 | 2024 | 63759 | 0.060 |
Why?
| | Biomarkers | 1 | 2016 | 3971 | 0.060 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 14 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2024 | 40 | 0.060 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 43 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2024 | 3384 | 0.060 |
Why?
| | Enterobacteriaceae | 1 | 2004 | 39 | 0.050 |
Why?
| | beta-Lactamases | 1 | 2024 | 41 | 0.050 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2003 | 13 | 0.050 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2003 | 38 | 0.050 |
Why?
| | Bronchopneumonia | 1 | 2003 | 6 | 0.050 |
Why?
| | Hospitals, Public | 1 | 2003 | 26 | 0.050 |
Why?
| | Nasopharynx | 1 | 2023 | 69 | 0.050 |
Why?
| | Escherichia coli Infections | 1 | 2003 | 108 | 0.050 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 51 | 0.050 |
Why?
| | Chorioamnionitis | 1 | 2003 | 40 | 0.050 |
Why?
| | Mycobacterium Infections | 1 | 2003 | 62 | 0.050 |
Why?
| | Ghana | 1 | 2022 | 34 | 0.050 |
Why?
| | Mycoses | 1 | 2003 | 73 | 0.050 |
Why?
| | Colorado | 4 | 2018 | 4410 | 0.050 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2002 | 36 | 0.050 |
Why?
| | Middle Aged | 4 | 2018 | 31177 | 0.050 |
Why?
| | Granuloma | 1 | 2002 | 90 | 0.050 |
Why?
| | HIV Seropositivity | 1 | 2002 | 120 | 0.050 |
Why?
| | Fetal Diseases | 1 | 2003 | 164 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 161 | 0.050 |
Why?
| | Bacterial Infections | 1 | 2003 | 234 | 0.040 |
Why?
| | Neisseria gonorrhoeae | 1 | 2021 | 24 | 0.040 |
Why?
| | Urban Health | 1 | 2021 | 79 | 0.040 |
Why?
| | Chlamydia trachomatis | 1 | 2021 | 46 | 0.040 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2002 | 267 | 0.040 |
Why?
| | Virus Diseases | 1 | 2003 | 210 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2021 | 14553 | 0.040 |
Why?
| | Risk Factors | 3 | 2018 | 9801 | 0.040 |
Why?
| | Prevalence | 2 | 2021 | 2564 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 176 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2010 | 1920 | 0.040 |
Why?
| | Telepathology | 1 | 2018 | 4 | 0.040 |
Why?
| | Morbidity | 1 | 2018 | 302 | 0.030 |
Why?
| | Pregnancy, Triplet | 1 | 2016 | 5 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 814 | 0.030 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2016 | 36 | 0.030 |
Why?
| | Lung Diseases | 1 | 2002 | 743 | 0.030 |
Why?
| | Twins, Monozygotic | 1 | 2016 | 209 | 0.030 |
Why?
| | HIV Infections | 1 | 2010 | 2730 | 0.030 |
Why?
| | Time | 1 | 2015 | 77 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 2015 | 69 | 0.030 |
Why?
| | Emigrants and Immigrants | 1 | 2016 | 122 | 0.030 |
Why?
| | Safety Management | 1 | 2015 | 113 | 0.030 |
Why?
| | Program Development | 1 | 2015 | 355 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 7 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 53 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 20 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 131 | 0.020 |
Why?
| | Crack Cocaine | 1 | 2010 | 7 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 135 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 878 | 0.020 |
Why?
| | Leukopenia | 1 | 2010 | 28 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 10241 | 0.020 |
Why?
| | Neutropenia | 1 | 2010 | 137 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2010 | 326 | 0.020 |
Why?
| | Informed Consent | 1 | 2010 | 165 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4896 | 0.020 |
Why?
| | Bone Marrow | 1 | 2010 | 272 | 0.020 |
Why?
| | Patient Compliance | 1 | 2010 | 568 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2003 | 63 | 0.010 |
Why?
| | Community-Acquired Infections | 1 | 2003 | 160 | 0.010 |
Why?
| | Prospective Studies | 1 | 2003 | 7158 | 0.010 |
Why?
|
|
Wilson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|